Results 101 to 110 of about 1,588,451 (244)

Vurdering av tester for PD-L1 ved urotelialt karsinom: en forenklet metodevurdering [PDF]

open access: yes, 2021
Hovedbudskap: Programmed cell death ligand 1 (PD-L1) på tumorceller kan binde til Programmed cell death protein 1 på immunceller og hindre disse i å bekjempe og nøytralisere kreftsvulster.
Brurberg, Kjetil Gundro   +2 more
core  

Single‐Dose TACE‐Like Injection of Sustained‐Release Panobinostat/IL‐12 Polymeric Microparticles is Effective in Preclinical Liver Cancer Models

open access: yesAdvanced Science, EarlyView.
A novel PLGA/PBAE polymer microparticle platform revolutionizes intermediate‐stage liver cancer treatment by co‐delivering panobinostat and IL‐12 via a single TACE‐like injection. This sustained‐release system overcomes tumor immunosuppression, triggers robust innate and adaptive immune responses, and establishes tertiary lymphoid structures ...
Hongzhe Yu   +7 more
wiley   +1 more source

In Situ Visualization of PD-L1-Specific Glycosylation on Tissue Sections

open access: yes, 2021
Immune checkpoint therapy has provided a weapon against cancer, but its response rate has been extremely low due to the lack of effective predictors.
Mengjiao Huang (2623792)   +21 more
core   +1 more source

Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer‐Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
A Transformer‐based AI framework, DLINP, screens millions of compounds to identify Co68, a cobalt‐pincer organometallic complex that biases TLR4‐MD2 signaling toward antitumor interferon activation while suppressing inflammatory toxicity through an early TLR4‐SYK‐STAT1 axis.
Xuefei Guo   +10 more
wiley   +1 more source

MZF1 Inhibits TGFβ‐1/SMAD Signaling by Transcriptionally Activating SnoN to Augment Tumorigenic Potential in Colon Cancer

open access: yesAdvanced Science, EarlyView.
This study identifies MZF1 as a core regulator of colon cancer via SnoN‐mediated TGF‐β suppression, proposes 10Panx Acetate as a targeted inhibitor, and validates MZF1/SnoN as prognostic markers for aggressive disease. ABSTRACT Colon cancer progression is associated with transcriptional and signaling abnormalities.
Siqi Sheng   +9 more
wiley   +1 more source

Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance

open access: yesIndian Journal of Ophthalmology, 2019
Purpose: Eyelid sebaceous gland carcinoma (SGC) is an aggressive but rare malignancy of ocular region. Over-expression of PD-L1 and PD-1 has been demonstrated in a variety of solid tumors including conjunctival melanoma.
Perumal Jayaraj, Seema Sen
doaj   +1 more source

Circulating tumour cell PD-L1 test for head and neck cancers

open access: yes, 2017
Immune checkpoint inhibitors have gained traction over the last few years in the treatment of metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) patients.
Chamindie Punyadeera   +5 more
core   +1 more source

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

open access: yesAdvanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert   +8 more
wiley   +1 more source

Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation

open access: yesAdvanced Science, EarlyView.
BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai   +7 more
wiley   +1 more source

Exosomal PD-L1 in cancer and other fields: recent advances and perspectives

open access: yesFrontiers in Immunology
PD-1/PD-L1 signaling is a key factor of local immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors targeting PD-1/PD-L1 signaling have achieved tremendous success in clinic.
Man-Man Lu, Yu Yang
doaj   +1 more source

Home - About - Disclaimer - Privacy